SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): INDV-1000

            Therapeutic Area: Psychiatry/Psychology Product Name: INDV-1000

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Indivior

            Deal Size: $4.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration July 29, 2021

            Details:

            INDV-1000 is a selective GABAb positive allosteric modulator for alcohol use disorder. The new funding will be used to prepare drug candidates for both Indivior’s substance use disorder program and Addex’s proprietary Charcot-Marie-Tooth type 1A neuropathy program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): SYT-510

            Therapeutic Area: Psychiatry/Psychology Product Name: SYT-510

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ysios Capital

            Deal Size: $26.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing April 20, 2021

            Details:

            This investment brings total Series A financing to CHF 24 million to complete pre-clinical development and progress lead candidate through proof-of-concept clinical studies. Synendos is advancing the preclinical and clinical development of SYT-510.